Supplemental Information (Tables)

9 Months Ended

Sep. 30, 2020

Geographic Areas, Long-Lived Assets [Abstract]

Schedule of Long-Lived Assets by Location

The following table presents long-lived assets by location:

	September 30, 2020		December 31, 2019
	Unaudited		Audited
United States	$	10,317	$	8,896
Switzerland	2,012		3,067
Israel	3,998		2,753
Japan	1,237		999
Germany	895		729
Others	944		582
Total long-term assets	$	19,403	$	17,026

Schedule of Revenues by Geographic Region

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:

	Three months ended September 30,				Nine months ended September 30,				Year ended December 31, 2019
	2020		2019		2020		2019
	Unaudited				Unaudited				Audited
United States	$	92,635	$	61,399	$	243,103	$	166,937	$	232,805
EMEA:
Germany	22,756		21,688		66,027		64,065		86,564
Other EMEA	5,468		2,794		12,069		5,442		8,782
Japan	7,523		4,779		21,153		12,334		17,912
Greater China (1)	4,278		1,402		8,061		3,306		5,255
Total net revenues	$	132,660	$	92,062	$	350,413	$	252,084	$	351,318

(1) Reflects revenue recognized in accordance with a License and Collaboration Agreement (the “Zai Agreement”) between the Company and Zai Lab (Shanghai) Co., Ltd. (“Zai”), dated September 10, 2018, pursuant to which Zai is commercializing Optune in China, Hong Kong, Macau and Taiwan (referred to in this table as “Greater China”). During the nine month period ended September 30, 2020, the Company triggered an $8,000 milestone related to the approval of Optune for the treatment of GBM in China and a $2,000 clinical trial milestone, each of which are being recognized over the remainder of the Zai performance period ending in September 2024. For additional information, see Note 12 to the Consolidated Financial Statements in the 2019 10-K.